Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Glycyrrhizic acid combined with human adipose-derived MSCs synergistically alleviates the MPP+/MPTP-induced parkinson's disease by inducing autophagy through PI3K/AKT/HIF-1α pathway.

Yu X., Fang Y., Zhang J., Li W., Zhang Y., Cui Q.

Animal Study on Neuroinflammation, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
40999534
PMCID
PMC12465595
DOI
10.1186/s13287-025-04626-6
Citations
5

Abstract (original English)

Aims Emerging research highlights the considerable therapeutic promise of glycyrrhizic acid (GA) and stem cells used separately for Parkinson's disease (PD). Nevertheless, the combined effects of GA and adipose-derived mesenchymal stem cells (ADSCs) in PD models have not been thoroughly investigated. This research is designed to evaluate the therapeutic potential of GA combined with ADSCs in vitro and in vivo, and to analyze the underlying molecular mechanisms. Main methods In vitro experiments were performed in SH-SY5Y cell. In vivo experiments were performed in C57BL/6 mice. Key findings In comparison to other treatment groups, the combination of GA and ADSCs exhibited improved therapeutic effects in vitro. RNA sequencing analysis revealed involvement of autophagy and the PI3K/AKT/HIF-1α signaling pathway in the treatment. In follow-up research, the combination of GA and ADSCs markedly increased the expression ratios of p-PI3K/PI3K, p-AKT/AKT, and p-mTOR/mTOR proteins in vitro following 1-methyl-4-phenylpyridinium (MPP+) exposure. Besides, the combined treatment downregulated the LC3II/LC3I expression ratio and Beclin-1 expression levels while upregulating p62, HIF-1α, and VEGFA expression levels. Similar to 3-MA, results from western blot, transmission electron microscopy (TEM) and immunofluorescence staining (IF) indicated that the combined treatment significantly reduced a

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AutophagyAnimalsHumansMesenchymal Stem CellsHypoxia-Inducible Factor 1, alpha SubunitPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktMiceGlycyrrhizic AcidMice, Inbred C57BL

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research